
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group is poised for continued success with a strong focus on developing innovative therapies for cancer and other diseases. The company's successful collaborations and expanding global presence demonstrate their strong scientific platform and potential for future growth. Additionally, Ascentage Pharma Group's strong patent portfolio and experienced leadership further solidify their position in the competitive oncology market.
Bears say
Ascentage Pharma Group is facing several fundamental challenges that have led to a negative outlook on its stock. These include a highly competitive market for its therapies, potential safety concerns around its lead drugs olverembatinib and lisaftoclax, and a high dependence on specific trial results in order to continue with funding operations. Additionally, the stock is sensitive to unexpected events, making it a risky investment.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares